Hamostaseologie最新文献_第2页

Women and Hereditary Bleeding Disorders.

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI: 10.1055/a-2462-6609

Alessandra Bosch, Dehlia Moussaoui, Alessandro Casini

{"title":"Women and Hereditary Bleeding Disorders.","authors":"Alessandra Bosch, Dehlia Moussaoui, Alessandro Casini","doi":"10.1055/a-2462-6609","DOIUrl":"https://doi.org/10.1055/a-2462-6609","url":null,"abstract":"Hereditary bleeding disorders encompass a range of hemostasis defects that impair the blood coagulation process. Although these disorders affect both men and women, research and clinical management have historically been predominantly focused on male patients, particularly those with hemophilia. Consequently, the impact of these disorders on women has been undervalued and frequently overlooked. The intricate relationship between a woman's tendency to bleed and the various gynecological and obstetric processes gives rise to distinctive health challenges for women with hereditary bleeding disorders. Heavy menstrual bleeding (HMB), excessive bleeding during miscarriages, postpartum hemorrhage, and hemorrhagic ovarian cysts represent some of the most common complications. Despite the high prevalence and significant impact of these symptoms, many women experience delays in diagnosis and treatment, which in turn may result in iron-deficiency anemia, anxiety, influence on reproductive decisions, and a decreased quality of life. This review aims to summarize the distinctive characteristics of hereditary bleeding disorders in women, emphasizing the clinical challenges and hormonal management strategies for HMB.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 1","pages":"70-79"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In Japan 40% Blutungskomplikationen während ECMO-Therapie bei COVID-19.

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI: 10.1055/s-0045-1804541

引用次数: 0

Basic Concepts and Indications of CAR T Cells.

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI: 10.1055/a-2491-3652

Jana van den Berg, Heinz Läubli, Nina Khanna, Lukas T Jeker, Andreas Holbro

引用次数: 0

Guidance-Based Appropriateness of Hemostasis Testing in the Acute Setting.

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI: 10.1055/a-2491-3631

Luigi Devis, Deepa J Arachchillage, Michael Hardy, Alexandre Mansour, Emilie Catry, Mélanie Closset, Isabelle Gouin-Thibault, Corinne Frere, Thomas Lecompte, Lorenzo Alberio, Janne Cadamuro, Giuseppe Lippi, François Mullier

{"title":"Guidance-Based Appropriateness of Hemostasis Testing in the Acute Setting.","authors":"Luigi Devis, Deepa J Arachchillage, Michael Hardy, Alexandre Mansour, Emilie Catry, Mélanie Closset, Isabelle Gouin-Thibault, Corinne Frere, Thomas Lecompte, Lorenzo Alberio, Janne Cadamuro, Giuseppe Lippi, François Mullier","doi":"10.1055/a-2491-3631","DOIUrl":"https://doi.org/10.1055/a-2491-3631","url":null,"abstract":"In this review, we aim to highlight the extent of inappropriate hemostasis testing and provide practical guidance on how to prevent it. We will focus on the acute setting, including but not limited to the emergency department and intensive care unit. To this end, we will first discuss the significance of inappropriateness, in the general context of laboratory medicine. This includes acknowledging the importance of the phenomenon and attempting to define it. Next, we describe the harmful consequences of inappropriate testing. Finally, we focus on the inappropriate use of hemostasis testing in the acute setting. The second section describes how interventions-in particular, the implementation of guidance for testing-can efficiently reduce inappropriateness. In the third section, we summarize the available recommendations for rational use of hemostasis testing (platelet count, activated partial thromboplastin time, prothrombin time/international normalized ratio, fibrinogen, thrombin time, D-dimer, anti-Xa assay, antithrombin, ADAMTS13 activity, antiheparin-PF4 antibodies, viscoelastometric tests, coagulation factors, and platelet function testing), as supported by guidelines, recommendations, and/or expert opinions. Overall, this review is intended to be a toolkit in the effort to promote the appropriate use of hemostasis testing. Hopefully, the new In Vitro Diagnostic Medical Device Regulation (EU) 2017/746 (IVDR) should help in improving the availability of evidence regarding clinical performance of hemostasis assays.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 1","pages":"24-48"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Signal Transduction and Transformation by the Platelet Activation Cascade: Systems Biology Insights.

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI: 10.1055/a-2486-6758

Anastasia N Sveshnikova, Mikhail Aleksandrovich Panteleev

{"title":"Signal Transduction and Transformation by the Platelet Activation Cascade: Systems Biology Insights.","authors":"Anastasia N Sveshnikova, Mikhail Aleksandrovich Panteleev","doi":"10.1055/a-2486-6758","DOIUrl":"10.1055/a-2486-6758","url":null,"abstract":"Binding of platelet activators to their receptors initiates a signal transduction network, where intracellular signal is filtered, amplified, and transformed. Computational systems biology methods could be a powerful tool to address and analyze dynamics and regulation of the crucial steps in this cascade. Here we review these approaches and show the logic of their use for a relatively simple case of SFLLRN-induced procoagulant activity. Use of a typical model is employed to track signaling events along the main axis, from the binding of the peptide to PAR1 receptor down to the mPTP opening. Temporal dynamics, concentration dependence, formation of calcium oscillations and their deciphering, and role of stochasticity are quantified for all essential signaling molecules and their complexes. The initial step-wise activation stimulus is transformed to a peak at the early stages, then to oscillation calcium spikes, and then back to a peak shape. The model can show how both amplitude and width of the peak encode the information about the activation level, and show the principle of decoding calcium oscillations via integration of the calcium signal by the mitochondria. Use of stochastic algorithms can reveal that the complexes of Gq, in particular the complex of phospholipase C with Gq, which are the limiting steps in the cascade with their numbers not exceeding several molecules per platelet at any given time; it is them that cause stochastic appearance of the signals downstream. Application of reduction techniques to simplify the system is demonstrated.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 1","pages":"49-62"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Die Gesellschaft für Thrombose- und Hämostaseforschung e.V. informiert.

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI: 10.1055/s-0045-1804539

引用次数: 0

Endometriose steigert Risiko für venöse Thrombembolien unter oraler Kontrazeption.

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI: 10.1055/s-0045-1804540

引用次数: 0

Aktueller Stand zur Reform der Gebührenordnung für Ärzte (GOÄ) und Veranstaltung des BDDH auf der 69. Tagung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) in Lausanne 2025.

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI: 10.1055/a-2343-6598

Jürgen Koscielny, Günther Kappert, Christoph Sucker

引用次数: 0

The Use of DOACs in Pediatrics: Current Therapeutic and Prophylactic Indications, Cardiac Indications, and Real-World Evidence-A Review.

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI: 10.1055/a-2486-6735

Alessandra Bosch, Martin Olivieri, Susanne Holzhauer

{"title":"The Use of DOACs in Pediatrics: Current Therapeutic and Prophylactic Indications, Cardiac Indications, and Real-World Evidence-A Review.","authors":"Alessandra Bosch, Martin Olivieri, Susanne Holzhauer","doi":"10.1055/a-2486-6735","DOIUrl":"https://doi.org/10.1055/a-2486-6735","url":null,"abstract":"Based on clinical trials that have been conducted and published in the past decade, direct oral anticoagulants (DOACs) are increasingly being used as an antithrombotic treatment in children with venous thrombotic events and to prevent thrombotic events in children at risk. In this review, current indications and standards for the initiation of DOACs in children are summarized for the treatment of venous thrombotic events and for the primary and secondary prevention in children at risk of developing thromboses based on the published randomized controlled trials (RCT). Similarly, indications for DOACs in children with underlying cardiac disease are portrayed based on RCT findings. Lastly, available real-world data are reviewed for the use of DOACs in pediatric patients with a focus on patients at higher risk of both thrombosis and bleeding who were primarily excluded from the RCTs. DOACs contribute largely to the evolving individualization of care of thrombotic events in children, but at-risk patient populations remain underrepresented regarding DOAC experience, such as preterm infants, and children with severe renal or hepatic disease. Real-world data from observational studies and registries will continue to be necessary to establish DOACs' effectiveness and safety in children in everyday clinical use.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 1","pages":"89-101"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antithrombotic Treatment for Left Ventricular Assist Devices: One Does Not Fit All.

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI: 10.1055/a-2487-6365

Emmanuelle Scala, Alexandra Othenin-Girard

{"title":"Antithrombotic Treatment for Left Ventricular Assist Devices: One Does Not Fit All.","authors":"Emmanuelle Scala, Alexandra Othenin-Girard","doi":"10.1055/a-2487-6365","DOIUrl":"https://doi.org/10.1055/a-2487-6365","url":null,"abstract":"As the prevalence of heart failure is increasing globally, left ventricular assist devices (LVADs) have become essential therapeutic options in managing advanced heart failure. This review explores the development of LVAD technology, with a focus on the shift from pulsatile to continuous-flow devices, particularly the HeartMate 3, the most advanced generation of LVADs. The evolution in design has significantly enhanced patient survival and quality of life. However, hemocompatibility-related adverse events (HRAEs)-such as pump thrombosis, ischemic and hemorrhagic strokes, and gastrointestinal bleeding-remain major clinical challenges. Striking the delicate balance between preventing thromboembolic events and minimizing hemorrhagic risks remains critical in LVAD patient management. Current therapeutic strategies typically involve long-term anticoagulation with vitamin K antagonists and antiplatelet therapy, though optimal management must be individualized based on patient-specific factors and device characteristics. Emerging alternatives, including low-dose anticoagulation, direct oral anticoagulants such as apixaban, and aspirin-free regimens, offer promising potential to reduce adverse outcomes. This review also highlights the role of innovative mechanical designs in minimizing shear stress and alternative treatments in preventing complications like gastrointestinal bleeding. Despite these advancements, personalized treatment strategies are critical, as no single therapeutic regimen fits all LVAD recipients. Ongoing research into both device technology and pharmacological therapies is essential to further reduce HRAEs and improve long-term outcomes for LVAD patients.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 1","pages":"80-88"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0